Atlas Trials

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Clinical trial NCT03507452 · COMPLETED

Trial details

NCT number
NCT03507452
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Recurrent Malignant Pleural Epithelioid MesotheliomaAdvanced Recurrent Malignant Peritoneal Epithelioid MesotheliomaAdvanced Recurrent Serous Ovarian CancerAdvanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
Start date
2018-06-13
Primary completion
2021-09-29
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.